基于BI决策支持系统的糖尿病药物集采量效研究OA

Objective To explore the establishment of a precise and effective management system cov-ering centralized procurement of diabetes drugs based on a BI decision support system.Methods In 2023,the Department of Pharmacy of the hospital implemented the BI decision support system for routine management of centralized drug procurement.Diabetic patients treated with centralized procurement drugs without the as-sistance of the BI decision support system from 2021 to 2022 were assigned as the control group,and those treated with centralized procurement drugs assisted by the BI decision support system from 2023 to 2024 were assigned as the experimental group.The procurement volume and implementation effects of centralized pro-curement of diabetes drugs were retrospectively analyzed.Results The proportion of centrally procured drugs in the experimental group(95.20%)was significantly higher than that in the control group(54.70%),the difference was statistically significant(P<0.05).At discharge,the fasting blood glucose[(6.76±0.94)mmol/L]and the rate of normoglycemia after treatment(80.20%)in the experimental group were significant-ly better than those in the control group[(11.16±0.68)mmol/L,62.39%].The incidence rates of ketoacido-sis(0.08%),hypoglycemia(0.44%),diabetic nephropathy at one year(1.12%),and diabetic foot(3.00%)in the experimental group were significantly lower than those in the control group(0.29%,1.89%,3.84%,and 11.00%,respectively),with statistically significant differences(P<0.05).Conclusion The BI decision sup-port system-assisted management model is conducive to improving the volume and effectiveness of centralized procurement of diabetes drugs.This model can serve as a reference template for the management of centralized drug procurement for diabetes in other hospitals.